UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 82 filers reported holding UROGEN PHARMA LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $367,000 | 0.0% | 21,560 | -6.4% | 0.01% | +16.7% |
| Q2 2021 | $367,000 | -50.1% | 23,044 | -41.9% | 0.01% | -53.8% |
| Q1 2021 | $735,000 | +24.6% | 39,692 | +21.7% | 0.01% | 0.0% |
| Q4 2020 | $590,000 | +6.5% | 32,603 | +13.7% | 0.01% | -27.8% |
| Q3 2020 | $554,000 | -17.7% | 28,684 | +8.4% | 0.02% | -25.0% |
| Q2 2020 | $673,000 | +57.2% | 26,454 | +12.1% | 0.02% | +20.0% |
| Q1 2020 | $428,000 | -41.5% | 23,590 | +9.8% | 0.02% | -20.0% |
| Q4 2019 | $731,000 | +53.6% | 21,494 | +8.2% | 0.02% | +47.1% |
| Q3 2019 | $476,000 | -18.4% | 19,856 | +12.2% | 0.02% | -10.5% |
| Q2 2019 | $583,000 | +34.6% | 17,695 | +51.1% | 0.02% | -9.5% |
| Q1 2019 | $433,000 | -16.7% | 11,710 | -3.1% | 0.02% | -12.5% |
| Q4 2018 | $520,000 | +4.4% | 12,087 | +14.6% | 0.02% | +26.3% |
| Q3 2018 | $498,000 | +26.1% | 10,546 | +29.2% | 0.02% | -20.8% |
| Q1 2018 | $395,000 | +49.6% | 8,161 | +19.2% | 0.02% | +26.3% |
| Q4 2017 | $264,000 | – | 6,845 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |